Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution

(2016) Talia M. Muram et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Secukinumab withdrawal leads to loss of treatment responses in a majority of subjects with plaque psoriasis with retreatment resulting in rapid regain of responses: A pooled analysis of two phase 3 trials

(2016)   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral tofacitinib for psoriasis: what happens with interrupted treatment?

(2015) H. Alinia et al.   BRITISH JOURNAL OF DERMATOLOGY

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

(2015) R. Bissonnette et al.   BRITISH JOURNAL OF DERMATOLOGY

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

(2015) Ulrich Mrowietz et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis

(2014) April N. Naegeli et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Secukinumab retreatment-as-needed maintenance regimen: Efficacy and safety outcomes from the SCULPTURE study

(2014)   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study

(2014) C.E.M. Griffiths et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis

(2013) U. Mrowietz et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study

(2012) K. Papp et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy

(2012) Elizabeth A. Brezinski et al.   PLoS One

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

(2010) K. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY